- Home
- NAMS vs WRBY Comparison
NAMS vs WRBY Comparison
Compare NAMS & WRBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMS
- WRBY
- Stock Information
- Founded
- NAMS 2019
- WRBY 2010
- Country
- NAMS Netherlands
- WRBY United States
- Employees
- NAMS N/A
- WRBY N/A
- Industry
- NAMS Biotechnology: Pharmaceutical Preparations
- WRBY Ophthalmic Goods
- Sector
- NAMS Health Care
- WRBY Health Care
- Exchange
- NAMS Nasdaq
- WRBY Nasdaq
- Market Cap
- NAMS 2.3B
- WRBY 1.9B
- IPO Year
- NAMS N/A
- WRBY 2021
- Fundamental
- Price
- NAMS $20.12
- WRBY $23.26
- Analyst Decision
- NAMS Strong Buy
- WRBY Buy
- Analyst Count
- NAMS 6
- WRBY 10
- Target Price
- NAMS $33.80
- WRBY $18.90
- AVG Volume (30 Days)
- NAMS 634.7K
- WRBY 1.7M
- Earning Date
- NAMS 11-06-2024
- WRBY 11-07-2024
- Dividend Yield
- NAMS N/A
- WRBY N/A
- EPS Growth
- NAMS N/A
- WRBY N/A
- EPS
- NAMS N/A
- WRBY N/A
- Revenue
- NAMS $33,594,000.00
- WRBY $742,527,000.00
- Revenue This Year
- NAMS N/A
- WRBY $16.59
- Revenue Next Year
- NAMS N/A
- WRBY $13.07
- P/E Ratio
- NAMS N/A
- WRBY N/A
- Revenue Growth
- NAMS 78.77
- WRBY 13.47
- 52 Week Low
- NAMS $8.90
- WRBY $10.28
- 52 Week High
- NAMS $26.35
- WRBY $23.39
- Technical
- Relative Strength Index (RSI)
- NAMS 44.60
- WRBY 85.44
- Support Level
- NAMS $19.59
- WRBY $21.05
- Resistance Level
- NAMS $25.32
- WRBY $23.39
- Average True Range (ATR)
- NAMS 1.44
- WRBY 0.91
- MACD
- NAMS -0.32
- WRBY 0.33
- Stochastic Oscillator
- NAMS 36.35
- WRBY 97.88
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About WRBY Warby Parker Inc.
Warby Parker Inc is engaged in designing and developing designer prescription glasses and contacts, and providing the facility of eye exams and vision tests. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.